BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

Accurate quantification of minimal residual disease (MRD) during treatment of chronic myeloid leukemia (CML) guides clinical decisions. The conventional MRD method, RQ-PCR for BCR-ABL1 mRNA, reflects a composite of the number of circulating leukemic cells and the BCR-ABL1 transcripts per cell. BCR-A...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Pagani, Ilaria S., Dang, Phuong, Kommers, Ivar O., Goyne, Jarrad M., Nicola, Mario, Saunders, Verity A., Braley, Jodi, White, Deborah L., Yeung, David T., Branford, Susan, Hughes, Timothy P., Ross, David M.
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6269287/
https://ncbi.nlm.nih.gov/pubmed/29976745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.189787
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars